Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation

Cochrane Database of Systematic Reviews a er three to four weeks' treatment (MD -0.71, 95% CI -2.68 to 1.26, very low quality evidence). Only one study randomising 20 participants reported on adverse events, and reported that there were no adverse events with flunarizine or with placebo (very low quality evidence). One study with 18 participants reported no events of deterioration in mental state with diltiazem or with placebo (very low quality evidence). No studies reported on acceptability of treatment or on social confidence, social inclusion, social networks or personalised quality of life outcomes designated important to patients. Authors' conclusionsAvailable evidence from randomised controlled trials is extremely limited and very low quality, conclusions cannot be drawn. The e ects of calcium channel blockers for antipsychotic-induced tardive dyskinesia are unknown. Their use is experimental and should only be given in the context of well-designed randomised trials.

show abstract

Vitamin E for neuroleptic-induced tardive dyskinesia

McGrath

Soares‐Weiser

2001

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation

Cited by 6 publications

References 19 publications

Calcium channel blockers for neuroleptic-induced tardive dyskinesia

Calcium channel blockers for neuroleptic-induced tardive dyskinesia

Calcium channel blockers for antipsychotic-induced tardive dyskinesia

Vitamin E for neuroleptic-induced tardive dyskinesia

Contact Info

Product

Resources

About